Using PDX for Preclinical Cancer Drug Discovery: The Evolving Field

por Williams, Juliet A.
Publicado 2018

Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models

por Wang, Hui Qin, Halilovic, Ensar, Li, Xiaoyan, Liang, Jinsheng, Cao, Yichen, Rakiec, Daniel P, Ruddy, David A, Jeay, Sebastien, Wuerthner, Jens U, Timple, Noelito, Kasibhatla, Shailaja, Li, Nanxin, Williams, Juliet A, Sellers, William R, Huang, Alan, Li, Fang
Publicado 2017

KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer

por Krall, Elsa B, Wang, Belinda, Munoz, Diana M, Ilic, Nina, Raghavan, Srivatsan, Niederst, Matthew J, Yu, Kristine, Ruddy, David A, Aguirre, Andrew J, Kim, Jong Wook, Redig, Amanda J, Gainor, Justin F, Williams, Juliet A, Asara, John M, Doench, John G, Janne, Pasi A, Shaw, Alice T, McDonald III, Robert E, Engelman, Jeffrey A, Stegmeier, Frank, Schlabach, Michael R, Hahn, William C
Publicado 2017

Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer

por Krall, Elsa Beyer, Wang, Belinda, Munoz, Diana M, Ilic, Nina, Raghavan, Srivatsan, Niederst, Matthew J, Yu, Kristine, Ruddy, David A, Aguirre, Andrew J, Kim, Jong Wook, Redig, Amanda J, Gainor, Justin F, Williams, Juliet A, Asara, John M, Doench, John G, Janne, Pasi A, Shaw, Alice T, McDonald III, Robert E, Engelman, Jeffrey A, Stegmeier, Frank, Schlabach, Michael R, Hahn, William C
Publicado 2017